XOMA Stock Overview
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
XOMA Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.09 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$13.48 |
| Beta | 0.59 |
| 1 Month Change | 8.71% |
| 3 Month Change | 26.59% |
| 1 Year Change | 35.89% |
| 3 Year Change | -30.26% |
| 5 Year Change | 120.54% |
| Change since IPO | -99.46% |
Recent News & Updates
Recent updates
Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?
Apr 03
Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?
Sep 01Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates
Aug 11XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M
Aug 04Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically
May 08Xoma Gets The Spotlight
Sep 02Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade
Aug 20We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right
May 13Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?
May 11XOMA EPS misses by $0.55, misses on revenue
May 06XOMA gets milestone payment from Janssen Biotech
May 03XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality
Mar 17Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be
Mar 16Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?
Mar 09Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?
Feb 02
XOMA: A Royalty Aggregator To Watch
Jan 04XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?
Dec 29XOMA prices $22M offering of series A cumulative perpetual preferred stock
Dec 11Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?
Dec 01XOMA earns $2M milestone payment from Takeda
Nov 16XOMA receives first royalty payment from Agenus
Nov 11Shareholder Returns
| XOMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.6% | 1.5% | 1.2% |
| 1Y | 35.9% | 1.1% | 24.7% |
Return vs Industry: XOMA exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: XOMA exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| XOMA volatility | |
|---|---|
| XOMA Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XOMA's share price has been volatile over the past 3 months.
Volatility Over Time: XOMA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | www.xoma.com |
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Corporation Fundamentals Summary
| XOMA fundamental statistics | |
|---|---|
| Market cap | US$303.56m |
| Earnings (TTM) | -US$46.30m |
| Revenue (TTM) | US$4.76m |
63.8x
P/S Ratio-6.6x
P/E RatioIs XOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XOMA income statement (TTM) | |
|---|---|
| Revenue | US$4.76m |
| Cost of Revenue | US$143.00k |
| Gross Profit | US$4.62m |
| Other Expenses | US$50.92m |
| Earnings | -US$46.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 96.99% |
| Net Profit Margin | -973.16% |
| Debt/Equity Ratio | 139.8% |
How did XOMA perform over the long term?
See historical performance and comparison